Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-16, Stock:ABBV, The news for the past five days is as follows:
2018-04-09: NEWS1: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS2: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS3: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis.NEWS4: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.NEWS5: [$$] Merck eyes best day since 2016, gains help fuel pharma rally.
2018-04-10: NEWS1: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS2: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS3: AbbVie&apos;s RA Candidate Meets Primary Endpoints in Phase III.NEWS4: AbbVie Stock Performance in 1Q18.NEWS5: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS6: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS7: FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS8: UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS9: FDA extends review for AbbVie, Neurocrine's uterine pain drug.NEWS10: AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain.NEWS11: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS12: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS13: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS14: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.NEWS15: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.
2018-04-11: NEWS1: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS2: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS3: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS4: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS5: FDA Prolongs Review Date for AbbVie Endometriosis Candidate.NEWS6: Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis.NEWS7: Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018.NEWS8: A Look at Eli Lilly’s 1Q18 Stock Performance.NEWS9: Is Gilead Sciences, Inc. (GILD) a Buy?.NEWS10: AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch.NEWS11: AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch.
2018-04-12: NEWS1: Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar.NEWS2: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS3: J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?.NEWS4: AbbVie Stock Is Signaling That a Move to the Upside Could Be Near.NEWS5: Olumiant Could Boost Incyte’s Revenues.
2018-04-13: NEWS1: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV&apos;s Drugs Succeed in Phase III.NEWS2: Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?.NEWS3: Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?.NEWS4: Better Buy: AbbVie Inc. vs. Eli Lilly.NEWS5: Better Buy: AbbVie Inc. vs. Eli Lilly.NEWS6: Exploring Voyager Therapeutics’ Research Pipeline.NEWS7: Better Buy: AbbVie Inc. vs. Eli Lilly.NEWS8: Another Shot At This 4-Time Winner -- If We Act Quickly.NEWS9: Another Shot At This 4-Time Winner -- If We Act Quickly.NEWS10: Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar.NEWS11: Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar.

Answer: Rise